keyword
MENU ▼
Read by QxMD icon Read
search

Dutasteride Tamsulosine

keyword
https://www.readbyqxmd.com/read/27551761/interactions-between-medications-employed-in-treating-benign-prostatic-hyperplasia-and-food-a-short-review
#1
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Benign prostatic hyperplasia (BPH) is the most common disease in elderly men. BPH symptoms include frequent urination, urgent tenesmus and urination at night, a weak and interrupted urine flow and a sense of incomplete emptying of the bladder. Alpha- 1 adrenergic receptor antagonists and 5 α-reductase inhibitors form the most important groups of medications employed in BPH. Appropriately managed BPH patients shall be subject to counselling on interactions between agents belonging to these groups, and on particular components of the food they have...
October 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27529214/apoptotic-pathways-linked-to-endocrine-system-as-potential-therapeutic-targets-for-benign-prostatic-hyperplasia
#2
REVIEW
Letteria Minutoli, Mariagrazia Rinaldi, Herbert Marini, Natasha Irrera, Giovanni Crea, Cesare Lorenzini, Domenico Puzzolo, Andrea Valenti, Antonina Pisani, Elena B Adamo, Domenica Altavilla, Francesco Squadrito, Antonio Micali
Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27388750/a-cost-effective-analysis-of-fixed-dose-combination-of-dutasteride-and-tamsulosin-compared-with-dutasteride-monotherapy-for-benign-prostatic-hyperplasia-in-nigeria-a-middle-income-perspective-using-an-interactive-markov-model
#3
Emeka I Udeh, Chimaobi G Ofoha, David A Adewole, Ikenna I Nnabugwu
BACKGROUND: The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy from the health service provider perspective design...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27356530/impact-of-formulation-on-the-pharmacokinetics-of-dutasteride-results-from-two-phase-i-studies
#4
Michael Fossler, John Zhu, Claus Roehrborn, Paul McAleese, Michael Manyak
BACKGROUND AND OBJECTIVES: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. METHODS: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0...
September 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27334136/can-we-use-baseline-characteristics-to-assess-which-men-with-moderately-symptomatic-benign-prostatic-hyperplasia-at-risk-of-progression-will-benefit-from-treatment-a-post-hoc-analysis-of-data-from-the-2-year-conduct-study
#5
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Juan Manuel Palacios, Averyan Vasylyev, Michael J Manyak
PURPOSE: To investigate (in a post hoc analysis of the 2-year CONDUCT study) the characteristics and clinical outcomes of men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression who benefitted from lifestyle changes alone. METHODS: Patients were given lifestyle advice and randomized to a fixed-dose combination (FDC) of dutasteride and tamsulosin or watchful waiting (WW) and followed for 24 months. Patients in the WW group were escalated to tamsulosin if any follow-up International Prostate Symptom Score (IPSS) was equal or greater than the baseline value...
June 22, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27137714/effect-of-tamsulosin-on-the-pharmacokinetics-of-dutasteride-in-chinese-male-healthy-volunteers
#6
Huafang Li, Jiansong Yang, Hongxin Zhao, Michael J Fossler, Chunrong Wang
The purpose of this study was to evaluate the effect of tamsulosin (0.2 mg) on the pharmacokinetics of dutasteride (0.5 mg) in a group of healthy Chinese male volunteers. This was an open-label, single-sequence, 3-period, drug-drug interaction phase 1 study. Twenty-four healthy Chinese male volunteers were enrolled and administered a single dose of 0.5 mg dutasteride and, following a 28- to 30-day washout period, 0.2 mg tamsulosin once daily for 7 days. On day 5, subjects received 0.2 mg tamsulosin coadministered with 0...
November 2015: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/26834837/fixed-dose-combination-therapy-with-dutasteride-and-tamsulosin-in-the-management-of-benign-prostatic-hyperplasia
#7
REVIEW
Konstantinos Dimitropoulos, Stavros Gravas
Despite their multifactorial etiology, male lower urinary tract symptoms (LUTS) have been traditionally associated with benign prostatic enlargement (BPE) because of benign prostatic hyperplasia (BPH). Several pharmaceutical therapies have been used to manage LUTS, with α1-adrenergic receptor antagonists (α1-blockers) and inhibitors of 5α-reductase (5α-RIs) representing the most commonly prescribed agents currently in use for LUTS treatment. Due to their different modes of action, combined use of α1-blockers and 5α-RIs has been proven to offer more optimal control of symptoms and better associated quality of life, even though higher rates of adverse events have been shown...
February 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/26824527/transitional-zone-index-as-a-predictor-of-the-efficacy-of-%C3%AE-blocker-and-5%C3%AE-reductase-inhibitor-combination-therapy-in-korean-patients-with-benign-prostatic-hyperplasia
#8
Jae Duck Choi, Jung Hoon Kim, Seung Hyun Ahn
INTRODUCTION: We investigated the value of the transitional zone index (TZI) for predicting treatment response to combination therapy involving α-blockers and 5α-reductase inhibitors for benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Symptomatic BPH patients (n = 118) were randomized to receive 0.2 mg tamsulosin alone or with 0.5 mg dutasteride daily for 12 months. The TZI, International Prostate Symptom Scores, maximum urinary flow rates (Qmax), postvoid residual urine volumes, and prostate-specific antigen (PSA) were evaluated at baseline and after 12 months...
2016: Urologia Internationalis
https://www.readbyqxmd.com/read/26166130/comparative-effectiveness-and-safety-of-monodrug-therapies-for-lower-urinary-tract-symptoms-associated-with-benign-prostatic-hyperplasia-a-network-meta-analysis
#9
Jin-Qiu Yuan, Chen Mao, Samuel Yeung-Shan Wong, Zu-Yao Yang, Xiao-Hong Fu, Xiao-Yu Dai, Jin-Ling Tang
A wide array of drugs are available for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), but the evidence for the comparative effectiveness is controversial.The objective of this study is to evaluate the comparative effectiveness and safety of monodrug therapies for BPH.Data sources are MEDLINE, EMBASE, and the Cochrane Library.We included randomized controlled trials that compared α-blockers, 5-alpha reductase inhibitors (5ARIs), muscarinic receptor antagonists (MRAs), phosphodiesterase-5 inhibitor (PDE5-Is), or placebo for the treatment of BPH...
July 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26104505/appropriateness-of-oral-drugs-for-long-term-treatment-of-lower-urinary-tract-symptoms-in-older-persons-results-of-a-systematic-literature-review-and-international-consensus-validation-process-luts-forta-2014
#10
REVIEW
Matthias Oelke, Klaus Becher, David Castro-Diaz, Emmanuel Chartier-Kastler, Mike Kirby, Adrian Wagg, Martin Wehling
AIM: we aimed to systematically review drugs to treat lower urinary tract symptoms (LUTS) regularly used in older persons to classify appropriate and inappropriate drugs based on efficacy, safety and tolerability by using the Fit fOR The Aged (FORTA) classification. METHODS: to evaluate the efficacy, safety and tolerability of drugs used for treatment of LUTS in older persons, a systematic review was performed. Papers on clinical trials and summaries of individual product characteristics were analysed regarding efficacy and safety in older persons (≥65 years)...
September 2015: Age and Ageing
https://www.readbyqxmd.com/read/26053014/finasteride-not-tamsulosin-increases-severity-of-erectile-dysfunction-and-decreases-testosterone-levels-in-men-with-benign-prostatic-hyperplasia
#11
Abdulmaged M Traish, Karim Sultan Haider, Gheorghe Doros, Ahmad Haider
BACKGROUND: 5α-reductase inhibitors (5α-RIs) (finasteride and dutasteride) have been proven useful in treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). However, these inhibitors exert undesirable sexual side effects and, in some cases, these effects are persistent. There is considerable disagreement with regard to whether the adverse side effects resolve with continuous treatment. AIM: To investigate the long-term adverse effects of finasteride treatment in men with BPH on erectile function and to compare these adverse effects in men treated with the α1-adrenergic receptor blocker, tamsolusin...
September 2015: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/25565364/efficacy-and-safety-of-a-fixed-dose-combination-of-dutasteride-and-tamsulosin-treatment-duodart-%C3%A2-compared-with-watchful-waiting-with-initiation-of-tamsulosin-therapy-if-symptoms-do-not-improve-both-provided-with-lifestyle-advice-in-the-management-of-treatment
#12
RANDOMIZED CONTROLLED TRIAL
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Fang Wang, Juan Manuel Palacios, Averyan Vasylyev, Michael J Manyak
OBJECTIVE: To investigate whether a fixed-dose combination (FDC) of 0.5 mg dutasteride and 0.4 mg tamsulosin is more effective than watchful waiting with protocol-defined initiation of tamsulosin therapy if symptoms did not improve (WW-All) in treatment-naïve men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression. PATIENTS AND METHODS: This was a multicentre, randomised, open-label, parallel-group study (NCT01294592) in 742 men with an International Prostate Symptom Score (IPSS) of 8-19, prostate volume ≥30 mL and total serum PSA level of ≥1...
September 2015: BJU International
https://www.readbyqxmd.com/read/25338730/the-effect-of-competing-direct-to-consumer-advertising-campaigns-on-the-use-of-drugs-for-benign-prostatic-hyperplasia-time-series-analysis
#13
Sean C Skeldon, Katy B Kozhimannil, Sumit R Majumdar, Michael R Law
BACKGROUND: Direct-to-consumer advertising (DTCA) remains a controversial issue, with concerns that it leads to unnecessary and inappropriate prescribing. Whether DTCA shifts prescribing from first-line (guideline-recommended) therapy to second-line drugs has not been studied. OBJECTIVE: The purpose of this study was to determine the impact of sequential DTCA campaigns for two drugs used to treat benign prostatic hyperplasia (BPH): one newer agent, dutasteride (Avodart(®)), and one older first-line agent, tamsulosin (Flomax(®))...
April 2015: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/25255740/dutasteride-plus-tamsulosin-fixed-dose-combination-first-line-therapy-versus-tamsulosin-monotherapy-in-the-treatment-of-benign-prostatic-hyperplasia-a-budget-impact-analysis-in-the-greek-healthcare-setting
#14
Maria Geitona, Pinelopi Karabela, Ioannis A Katsoulis, Hara Kousoulakou, Eleni Lyberopoulou, Eleftherios Bitros, Loukas Xaplanteris, Sotiria Papanicolaou
BACKGROUND: The purpose of this study was to explore the budget impact of dutasteride plus tamsulosin fixed-dose combination (DUT + TAM FDC) versus tamsulosin monotherapy, in the treatment of patients with benign prostatic hyperplasia (BPH) from the perspective of the Greek healthcare insurance system. METHODS: A Microsoft Excel-based model was developed to estimate the financial consequences of adopting DUT + TAM FDC within the Greek healthcare setting. The model, compared six mutually exclusive health states in two alternative treatment options: current standard of care and the introduction of DUT + TAM FDC in the market...
2014: BMC Urology
https://www.readbyqxmd.com/read/24823464/5%C3%AE-reductase-type-1-modulates-insulin-sensitivity-in-men
#15
RANDOMIZED CONTROLLED TRIAL
Rita Upreti, Katherine A Hughes, Dawn E W Livingstone, Calum D Gray, Fiona C Minns, David P Macfarlane, Ian Marshall, Laurence H Stewart, Brian R Walker, Ruth Andrew
CONTEXT: 5α-Reductase (5αR) types 1 and 2 catalyze the A-ring reduction of steroids, including androgens and glucocorticoids. 5α-R inhibitors lower dihydrotestosterone in benign prostatic hyperplasia; finasteride inhibits 5αR2, and dutasteride inhibits both 5αR2 and 5αR1. In rodents, loss of 5αR1 promotes fatty liver. OBJECTIVE: Our objective was to test the hypothesis that inhibition of 5αR1 causes metabolic dysfunction in humans. DESIGN, SETTING, AND PARTICIPANTS: This double-blind randomized controlled parallel group study at a clinical research facility included 46 men (20-85 years) studied before and after intervention...
August 2014: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/24804842/nocturia-improvement-in-the-combination-of-avodart-%C3%A2-and-tamsulosin-combat-study
#16
RANDOMIZED CONTROLLED TRIAL
Matthias Oelke, Claus G Roehrborn, Carlos D'Ancona, Timothy H Wilson, Ramiro Castro, Michael Manyak
PURPOSE: The purpose of the study was to assess the impact of dutasteride plus tamsulosin combination therapy, compared with dutasteride or tamsulosin monotherapy, on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) using data from the 4-year CombAT study. METHODS: Nocturia was assessed using Question 7 of the International Prostate Symptom Score questionnaire. Efficacy measures included as follows: mean change in nocturia at 3-month intervals up to 48 months; proportion of patients with improvement/worsening in nocturia; nocturnal voiding frequency at baseline and study end, overall and by baseline subgroups; and nocturnal voiding frequency <2 at study end in patients with a baseline score ≥ 2...
October 2014: World Journal of Urology
https://www.readbyqxmd.com/read/24708055/impact-of-medical-treatments-for-male-lower-urinary-tract-symptoms-due-to-benign-prostatic-hyperplasia-on-ejaculatory-function-a-systematic-review-and-meta-analysis
#17
REVIEW
Mauro Gacci, Vincenzo Ficarra, Arcangelo Sebastianelli, Giovanni Corona, Sergio Serni, Shahrokh F Shariat, Mario Maggi, Filiberto Zattoni, Marco Carini, Giacomo Novara
INTRODUCTION: Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side effects, including ejaculatory dysfunction (EjD). AIM: To provide a systematic review and meta-analysis of the available randomized clinical trials (RCTs) reporting the impact of medical treatments for LUTS due to BPH on ejaculatory function. MAIN OUTCOME MEASURE: EjD related to medical treatments for LUTS...
June 2014: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/24615171/pharmacokinetic-bioequivalence-studies-of-a-fixed-dose-combination-of-tamsulosin-and-dutasteride-in-healthy-volunteers
#18
RANDOMIZED CONTROLLED TRIAL
Michael J Fossler, David A Collins, Meg M Thompson, Antonio Nino, Joseph J Bianco, Dushen Chetty
BACKGROUND AND OBJECTIVES: The combination of dutasteride and tamsulosin may be more effective for the treatment of symptomatic benign prostatic hyperplasia than either treatment alone. We report the results of three pharmacokinetics and tolerability studies, which used a dutasteride/tamsulosin HCl (0.5 mg/0.2 mg) fixed-dose combination (FDC) capsules containing a small dutasteride soft gelatin capsule (smaller than commercial Avodart™) and modified-release tamsulosin pellets that have different amounts of enteric coating...
May 2014: Clinical Drug Investigation
https://www.readbyqxmd.com/read/24500194/efficacy-and-safety-of-dutasteride-for-the-treatment-of-symptomatic-benign-prostatic-hyperplasia-bph-a-systematic-review-and-meta-analysis
#19
REVIEW
Taehwan Park, Jae-Young Choi
PURPOSE: To determine the efficacy and safety of dutasteride, alone or in combination, versus a placebo or control, used for the treatment of benign prostatic hyperplasia. METHODS: Pubmed(®) and the Cochrane Library were searched for randomized controlled trials longer than 6 months in duration. The subjects in the trials were men aged 40 or over, with moderate to severe symptoms of benign prostatic hyperplasia (BPH) as determined by International Prostate Symptom Score (IPSS)...
August 2014: World Journal of Urology
https://www.readbyqxmd.com/read/24466398/clinical-effects-of-discontinuing-5-alpha-reductase-inhibitor-in-patients-with-benign-prostatic-hyperplasia
#20
Won Kim, Jae Hung Jung, Tae Wook Kang, Jae Mann Song, Hyun Chul Chung
PURPOSE: To assess changes in lower urinary tract symptoms (LUTS), prostate volume, and serum prostate-specific antigen (PSA) after discontinuation of 5-alpha reductase inhibitor (5ARI) combination therapy in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: From December 2003 to December 2012, data were collected retrospectively from 81 men more than 40 years of age with moderate to severe BPH symptoms (International Prostate Symptom Score [IPSS]≥8)...
January 2014: Korean Journal of Urology
keyword
keyword
27049
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"